Seven Bridges Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Seven Bridges Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,196	Closed	-$95K	–	151
2016 Q1	$95K	Buy	1,196 +593	+98%	+$53.6K	0.08%	134
2015 Q4	$76K	Buy	+603	New	+$72.8K	0.08%	141

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Seven Bridges Advisors's VRTX Position: Q2 2016 in Review

Seven Bridges Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 1,196 shares — an estimated $95K sold.

Seven Bridges Advisors first reported a position in VRTX in Q4 2015 and held it in 2 quarters. The position peaked at $95K in Q1 2016. 482 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Seven Bridges Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Seven Bridges Advisors sold 1,196 Vertex Pharmaceuticals shares in Q2 2016, an estimated $95K.
Seven Bridges Advisors first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 2 quarters.
Seven Bridges Advisors's Vertex Pharmaceuticals position peaked at $95K in Q1 2016.
482 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Seven Bridges Advisors's 13F filing for Q2 2016, filed 25 Jul 2016.